創元科技(000551.SZ):目前沒有和宇樹機器人合作
格隆匯7月30日丨創元科技(000551.SZ)在互動平臺表示,公司控股子公司蘇州軸承生產的滾針軸承產品可以細分爲向心滾針軸承、推力滾針軸承、圓柱滾子軸承、滾輪滾針軸承、單向軸承等,產品廣泛應用於汽車的轉向系統、主動安全系統、傳動系統、扭矩管理系統、新能源電驅系統、智能座椅系統、變速箱、發動機和空調壓縮機等重要總成,同時還應用於工業自動化、高端裝備、機器人、工程機械、減速機、液壓傳動系統、電動工具、紡機、農林機械、航空航天、國防工業等領域。 公司目前沒有和宇樹機器人合作。公司控股子公司蘇州軸承未來將加大新能源汽車和國防、航空航天、機器人、工業自動化和高端裝備領域的客戶開發和產品的研發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.